deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02896127

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis

Sponsor: Novartis Pharmaceuticals

Conditions Ankylosing Spondyloarthritis
Interventions Placebo Secukinumab
Updated 18 times since 2017 Last updated: Dec 4, 2020 Started: Oct 18, 2016 Primary completion: May 14, 2018 Completion: Mar 19, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02896127, this PHASE3 trial focuses on Ankylosing Spondyloarthritis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 18 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 13 earlier versions

  1. Nov 2019 — Apr 2020 [monthly]

    Completed PHASE3

  2. Sep 2019 — Nov 2019 [monthly]

    Completed PHASE3

  3. Aug 2019 — Sep 2019 [monthly]

    Completed PHASE3

  4. May 2019 — Aug 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  11. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  12. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bath, United Kingdom , Beijing, China , Bengbu, China , Bradford, United Kingdom , Bruntál, Czechia , Busan, South Korea , Changsha, China , Chengdu, China , Doncaster, United Kingdom , Guangzhou, China and 23 more locations